Innate Pharma Presents Data From Ongoing Phase 2 TELLOMAK Trial Demonstrating Clinical Activity of Lacutamab in Advanced Sézary Syndrome at ASH 2022
Retrieved on:
Saturday, December 10, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Therapy, CD16, Lymphatic system, Novo Nordisk, IND, Mycosis fungoides, Cancer, PTCL, AstraZeneca, Peripheral T-cell lymphoma not otherwise specified, Tumor microenvironment, Euronext Paris, Natural killer T cell, Fast Track, Mature T-cell lymphoma, Union, Skin, Bristol Myers Squibb, KIR3DL2, Tetra, Hematopoietic stem cell transplantation, US Foods, Cell, Blood, Degenerative disease, NCR1, Lymphoma, NK, T-cell lymphoma, CTCL, Peripheral T-cell lymphoma, ASH, Food and Drug Administration, Immune system, ORR, Doctor of Philosophy, EMA, Patient, DVM, Family, Division, FDA, KIR, European Medicines Agency, Antibody, Caregiver, Publication, Sanofi, Pharmaceutical industry, Vaccine, Intrinsic and extrinsic properties, MD, EU
In line with previous observations, lacutamab demonstrated a favorable safety profile for patients with advanced Szary syndrome in the TELLOMAK Phase 2 preliminary analysis.
Key Points:
- In line with previous observations, lacutamab demonstrated a favorable safety profile for patients with advanced Szary syndrome in the TELLOMAK Phase 2 preliminary analysis.
- The data continues to support our fast to market strategy for lacutamab in the niche setting of Szary syndrome where lacutamab was granted U.S. Fast Track designation and EU Prime designation.
- We thank the investigators, clinical research coordinators, patients and caregivers involved in the ongoing TELLOMAK program.
- Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.